Nonhomologous end joining (NHEJ) is a critical DNA repair pathway, with proposed tumor suppression functions in many tissues. Mutations in the NHEJ factor ARTEMIS cause radiation-sensitive severe combined immunodeficiency in humans and may increase susceptibility to lymphoma in some settings. We now report that deficiency for Artemis (encoded by Dclre1c/Art in mouse) accelerates tumorigenesis in several tissues in a Trp53 heterozygous setting, revealing tumor suppression roles for NHEJ in lymphoid and non-lymphoid cells. We also show that B-lineage lymphomas in these mice undergo loss of Trp53 heterozygosity by allele replacement, but arise by mechanisms distinct from those in Art Trp53 double null mice. These findings demonstrate a general tumor suppression function for NHEJ, and reveal that interplay between NHEJ and Trp53 loss of heterozygosity influences the sequence of multi-hit oncogenesis. We present a model where p53 status at the time of tumor initiation is a key determinant of subsequent oncogenic mechanisms. Because Art deficient mice represent a model for radiationsensitive severe combined immunodeficiency, our findings suggest that these patients may be at risk for both lymphoid and non-lymphoid cancers.
Introduction
Nonhomologous end joining (NHEJ) is a critical pathway for DNA double strand break (DSB) repair in eukaryotic cells. Cells with mutations in NHEJ genes exhibit chromosomal instability, hypersensitivity to ionizing radiation (IR), increased cellular senescence and proliferation defects, indicative of defects in the repair of spontaneous and induced DSBs (Ferguson and Alt, 2001; Jackson, 2002; Jeggo and Lobrich, 2006) . Mice with deficiencies in six of the seven known NHEJ factors have been isolated or engineered and show phenotypes ranging from variable B-, T-severe combined immunodeficiency (SCID), to IR sensitivity, to late embryonic lethality associated with extensive neuronal apoptosis (reviewed in Mills et al., 2003; Rooney et al., 2004a) . In humans, mutant alleles in the gene encoding the NHEJ factor ARTEMIS are the molecular basis for radiation-sensitive SCID (RS-SCID), and hypomorphic ARTEMIS alleles may be associated with increased lymphoma predisposition (Nicolas et al., 1998; Moshous et al., 2001 Moshous et al., , 2003 Ege et al., 2005) . The importance of NHEJ in genomic stability suggests that this pathway should suppress tumors in many somatic tissues, but roles for NHEJ in tumor suppression have primarily been characterized in B-lymphocytes.
Loss of heterozygosity (LOH) is a common genetic aberration in both sporadic and familial cancers (reviewed in Tischfield and Shao, 2003) . The critical tumor suppressor p53 (encoded by TP53 in humans and Trp53 in mice) is mutated in greater than half of all inherited and spontaneously arising human cancers, often through LOH. The importance of p53 is underscored by mouse studies showing that homozygous inactivation of the Trp53 gene results in the dramatic increase in broad-spectrum tumor incidence (Donehower et al., 1992; Jacks et al., 1994; Harvey et al., 1993) . Although the molecular mechanisms for LOH are poorly defined, DSBs have been suggested as initiating lesions, especially for deletional or recombinational mechanisms (Jasin, 2000; Lasko et al., 1991; Stark and Jasin, 2003) . This is supported by the observation that IR is associated with Trp53 LOH, leading to accelerated tumorigenesis in Trp53 N/ þ mice (Jiang et al., 2001; Liang et al., 2002) . In this context, specific functions of DSB repair pathways to prevent LOH are unknown.
We now report that Artemis deficiency accelerates tumorigenesis in several tissues and shifts the tumor spectrum in Trp53 N/ þ mice, demonstrating a multi-tissue tumor suppression function for NHEJ. In addition to non-lymphoid tumors, Art null Trp53 heterozygous mice (hereafter denoted Art N/N Trp53 N/ þ ) developed B lineage lymphomas reminiscent of those arising in NHEJ/Trp53 double null mice. These lymphomas showed LOH at Trp53, but, surprisingly, exhibited cytogenetic and molecular abnormalities distinct from those in NHEJ/Trp53 double null mice. We present a model for the interplay of NHEJ and Trp53 LOH, wherein p53 status at the time of initiation is a key determinant in the timing and order of multi-hit oncogenesis. 
Results

NHEJ suppresses tumor formation in multiple tissues
Trp53
N/ þ mice (34%) developed illness and were euthanized for analysis. Nine (9) lymphomas, two (2) anaplastic sarcomas, five (5) differentiated sarcomas and two (2) malignant gliomas were observed as well as several non-malignant pathologies. By contrast, none of the 39 control Trp53 N/ þ mice developed illness during the observation period, and statistical comparisons revealed the Art
N/ þ survival data sets to be highly significantly different (P ¼ 0.005). Finally, the Art N/N Trp53 N/ þ mice succumbed at a median age of 48 weeks, as compared with 62-64 weeks for Trp53 N/ þ mice ( Figure 1a ; Table 1 ). Consistent with previously published data, all (33/33) Art N/N Trp53 N/N mice rapidly developed fulminant lymphoma and succumbed by 16 weeks (Rooney et al., 2004b) . No Art
mice developed tumors during this study, consistent with previous reports (Rooney et al., 2002) .
To investigate the mechanistic basis for tumor development in Art N/N Trp53 N/ þ mice, detailed molecular and cytogenetic analyses were performed for three lymphomas and two sarcomas that were separable from surrounding normal tissue. Two of the lymphomas (AP546 and AP1605) presented as large focal lesions affecting multiple lymph nodes, whereas the third lymphoma (AP1043) presented as numerous discrete lesions primarily in the spleen and some lymph nodes. Flow cytometry (Figure 1c 
N/ þ sarcomas (AP1134 and AP1454) (Figure 2a ). PCR genotype analysis revealed loss of the wild type Trp53 allele in all three lymphomas but not the sarcomas. One lymphoma (AP1043) contained an additional lymph node tumor focus, which showed both wild type and null Trp53 alleles, suggesting an independently arising lymphoma with different p53 status in this mouse (Figure 2a ). However, array comparative genomic hybridization (CGH) revealed that all tumor foci from this mouse contained similar copy number abnormalities (CNAs) (data not shown), indicating that contaminating nontumor tissue likely contributed the wild-type Trp53 allele in this case. By contrast to the lymphomas, both sarcoma samples retained an intact wild-type Trp53 allele (Figure 2a ). These results indicate that, unlike the lymphomas, the formation of sarcomas in the absence of Art was not accompanied by overt loss of the wild-type Trp53 allele. Although it is possible that the wild-type band in the sarcomas was owing to contaminating normal tissue, this is not likely because, in both instances, DNA was isolated from tumor masses distinct and separate from adjacent normal tissue. However, we cannot rule out functional inactivation of p53 by other mechanisms not detected by this PCR strategy. Together, these data demonstrate that B lineage lymphomagenesis in Art N/N Trp53 N/ þ mice was accompanied by LOH for Trp53 in most, if not all, cases (hereafter denoted Art
Loss of Trp53 heterozygosity in lymphomas occurs by an allele replacement mechanism To determine whether Trp53 LOH resulted from a large interstitial deletion or other cytogenetic abnormality, fluorescence in situ hybridization (FISH) analysis was performed (Figure 2b and c). Metaphase chromosome spreads were prepared for the AP546 and AP1605 lymphomas, co-stained with a chromosome (Chr) 11-specific paint and a fluorescently labeled BAC probe containing the Trp53 locus and counterstained with DAPI (Figure 2b and c). Neither AP1605 nor AP546 showed evidence of a deletion affecting Trp53 on either allele, but in AP546 one Trp53 allele appeared near the junction of a translocation, shown by spectral karyotype (SKY) analysis to be a nonreciprocal der(11)t(1;11) ( Figures 2b, c and 4g ). Additional FISH mapping suggested that the translocation junction in this tumor was located within a BAC length (B200 kilobase pairs) proximal to Trp53 and that Chr 11 sequences proximal Figure 3 ). Together, these data ruled out large scale deletion and suggested that Trp53 LOH occurred either by small focal deletion or by allele replacement, rather than by large-scale deletion.
To distinguish between deletion and allele replacement LOH mechanisms, a quantitative PCR strategy (Q-PCR) was devised to measure the copy number of wild type versus knockout alleles (i.e. 0, 1, 2 or more copies per cell) ( Figure 3a ). Primers were designed to detect either a Trp53 knockout allele specific sequence (NEO), or a Trp53 locus sequence common to both the wild type and null alleles (COMMON). To calibrate this approach, Trp53 þ / þ and Trp53 N/N DNA samples were mixed at defined ratios, and either NEO or COMMON sequences were evaluated ( Figure 3b ; Supplementary methods). This demonstrated both linearity and sensitivity for the assay, showing that various ratios of NEO: COMMON sequences could be accurately quantified ( Figure 3b ). Analysis of the AP546 and AP1605 lymphomas by this method confirmed the presence of the null allele and absence of the normal Trp53. To discriminate between deletion and replacement of the normal Trp53 allele, the assay was repeated, comparing DC t values for NEO or COMMON sequences against a series of four unaffected 'normalizer' genes. Control samples showed NEO and COMMON sequences, both present in two copies (Figure 3c ). Analysis of tail DNA from AP1605 produced DC tCOMMON values near zero (0), and DC tNEO values close to 1 as expected, (Figure 3c ). By contrast, Art N/N Trp53 LOH lymphomas AP546 and AP1605 contained two copies of both NEO and COMMON sequences, indicating replacement of the wild type with the knockout allele (Figure 3b and c) . Analysis of tumor and non-tumor DNA from AP1043 revealed Chr 11 instability even in non-lymphoid tissues, precluding an accurate assessment of Trp53 copy number changes between germline and tumor. (1) a der(12) t(12;15) translocation and a complex der(15) complicon, harboring co-amplified c-myc and Igh loci; or (2) a der(12) complicon harboring co-amplified N-myc and Igh loci Rooney et al., 2004b) . Artemis in multi-tissue tumor suppression and LOH Y Woo et al (Figure 5d ) (Akilesh et al., 2003) . However, cytogenetic data demonstrated that this amplification was not associated either with a complicon or a simple translocation. Q-PCR also confirmed negligible amplification of c-myc and Igh in AP1605, supporting findings from CGH analysis (Figure 5d) . Interestingly, the AP546 lymphoma showed substantial amplification of Bcl11a and c-Rel, both of which map within the Chr 11 amplicon detected by array CGH. Together with SKY and FISH data showing an associated translocation, these findings indicate that Bcl11a and c-Rel, but not c-or N-myc, were involved in a complicon in this tumor, 
Cytogenetic lesions differ in
Discussion
We have shown that the NHEJ factor Artemis (encoded by Dclre1c/Art) acts in concert with p53 to suppress tumor formation in multiple tissues, demonstrating the general importance of NHEJ in tumor suppression beyond the lymphoid system. Deficiency for Artemis in Trp53 N/ þ mice both accelerated tumorigenesis and shifted the tumor spectrum associated with Trp53 heterozygosity. In addition to lymphomas, Art N/N Trp53 N/ þ mice developed osteosarcomas, anaplastic sarcomas and a range of non-malignant pathologies. Importantly, two brain tumors, which have been very rarely linked with mouse Trp53 deficiency but may be associated with human TP53-deficient syndromes, were observed in this study. Furthermore, lack of Art accelerated Trp53 LOH, often by an allele replacement mechanism, in progenitor B-lymphocytes. Significantly, we demonstrate that lymphomas arising subsequent to Trp53 LOH are not equivalent to those arising in mice that are fully null for Trp53 in the germline. This surprising finding indicates that p53 status at the time of tumor initiation influences the sequence and the timing of subsequent oncogenic events.
NHEJ is a multi-tissue tumor suppression pathway
To date, most studies implicating NHEJ in tumor suppression have focused on lymphoid cells, but an important role for NHEJ has also been postulated in non-lymphoid tumor suppression. NHEJ has recently been associated, in certain tissue-specific cases, with non-lymphoid tumor suppression. Tissue-specific inactivation of XRCC4 in Trp53 deficient neuronal progenitor cells, or Ku80/Trp53/Rag1 triple deficiency, both led to early onset medulloblastoma (Holcomb et al., 2006; Yan et al., 2006) . Similarly, heterozygosity for Lig4 in an Ink4/Arf null context led to accelerated formation of soft tissue sarcomas (Sharpless et al., 2001) . However, these studies all required compound engineered mutations with concomitant germline inactivation of a tumor suppressor to create a highly sensitized system. Moreover, it is unclear whether XRCC4 or Lig4 nullizygosity in mouse relates to true clinical oncogenesis in humans, where such alleles have not been identified.
In this context, Art N/N Trp53 N/ þ mice represent a more clinically relevant disease model with implications for understanding human cancer-prone and immunodeficient syndromes, such as Li-Fraumeni and Li-Fraumenilike syndromes (LFS and LFL, respectively) and radiation-sensitive (RS)-SCID. LFS and LFL are rare familial cancer syndromes characterized by predisposition to a wide spectrum of early onset tumors, including soft tissue sarcomas, breast cancer, adrenocortical carcinomas and brain tumors. Germline TP53 mutations account for approximately 70% of LFS cancer diagnoses and have been implicated in some, but not all, LFL cases (reviewed in Olivier et al., 2003) . Broad clinical heterogeneity, even within the same affected families, is often observed in both LFS and LFL, but the underlying reasons remain poorly understood. In this context, the latency and tumor spectrum in Art N/N Trp53 N/ þ mice, especially with respect to brain tumors, is reminiscent of some clinical features of LFS and LFL. Thus our data suggest that somatic DSB repair defects could influence the clinical heterogeneity and specific tumor development in some LFS or LFL patients and, in this regard, Art N/N Trp53 N/ þ mice may represent a good model for some aspects of LFS and LFL.
RS-SCID, another rare human disorder, is associated with hypomorphic mutations of ARTEMIS. Untreated RS-SCID patients usually succumb within 1 year of birth, but bone marrow transplantation has successfully restored immune function and extended survival in these patients (de Villartay et al., 2003) . Furthermore, a recent preclinical study demonstrated that lentiviral-mediated gene transfer can also restore immune function in Artemis null (RS-SCID) mice and may represent an attractive alternative to conventional therapies (Mostoslavsky et al., 2006) . Here, we have shown that deficiency for Art confers both lymphoid and nonlymphoid cancer risks in a Trp53 compromised setting. Our data demonstrate that the possibility of nonlymphoid malignancies, especially in successfully immunorestored RS-SCID patients with increased longevity, is a potentially major clinical concern. It will be important to determine whether inherited polymorphisms affecting TP53, or p53-associated pathways, interact with Artemis deficiency to modulate disease susceptibility or specific pathology. In this context, Art N/N Trp53 N/ þ mice may also serve as a clinically relevant model to study the interplay of DSB repair and TP53 in both lymphoid and non-lymphoid tumor suppression.
The p53 tumor suppressor determines event spectrum and sequence in multi-hit oncogenesis Our data indicate that Art, and by extension NHEJ, is important for prevention of certain LOH events, and that spontaneously occurring DSBs can initiate loss of Trp53 through allele replacement, at least in lymphocytes. Because complicon formation is an efficient transformation mechanism, we predicted that Trp53 LOH, as an early transforming step, would lead to lymphomas identical to those in Art N/N Trp53 N/N mice . However, this was not observed. Based on our observation that Art N/N
Trp53
LOH pro-B cell lymphomas unexpectedly developed molecular and cytogenetic features distinct from those in Art N/N Trp53 N/N tumors, we now propose a refined model for multi-hit tumorigenesis. By this model, p53 status at the time of tumor initiation influences the order and timing of subsequent events, even if p53 function is eventually lost (Figure 6 ). We propose that, before Trp53 LOH, Art N/N Trp53 N/ þ cells acquire a premalignant state, perhaps by activation of a weak protooncogene ( Figure 6 ). These cells become poised for full transformation but are prevented from overt neoplastic transformation through functional p53 activity. Abrogation of p53 by LOH then enables neoplastic progression and conversion to full malignancy. Complicon formation in Art N/N Trp53 LOH cells is circumvented because loss of p53 is sufficient for conversion to full malignancy, obviating the need for further oncogenic translocations or amplification. The rarity of complicon formation described in human tumors may, in part, be explained by the necessity for full loss of p53 function before the complicon-initiating translocation. In this regard, it is likely that the Art N/N Trp53 LOH tumorigenic mechanism described here more closely reflects many clinical situations, where partial p53 activity is retained, and is sufficient to resist complicon formation, thus favoring step-wise progression from premalignancy, through TP53 LOH, to disease. In this context, it will be interesting to determine whether complicon rates differ in sporadic tumors from patients with intact TP53 versus histologically similar tumors from LFS or LFL patients.
Clinical implications of this study
We show in this study that, in the absence of the NHEJ factor Artemis, multi-tissue tumorigenesis in a Trp53 heterozygous context is accelerated and the tumor spectrum is shifted. It will be interesting to determine whether mutations in Art or other NHEJ genes similarly interact with p53 to confer tumor susceptibility in humans, and to evaluate their mechanistic roles in preventing formation of oncogenic chromosomal lesions such as complicons. In this context, Art N/N Trp53 N/ þ mice may represent a model for some RS-SCID patients, who are potentially at risk for development of several types of cancer, and may provide insight into the clinical heterogeneity observed in familial cancer syndromes such as Li-Fraumeni and Li-Fraumeni-like. Another important implication of this study is that p53 allelotype in RS-SCID or other NHEJ-related human immunodeficient patients could prove to be a key predictive factor in specific tumor susceptibility as these patients age (de Villartay et al., 2003) .
Materials and methods
Mice heterozygous for a null allele of the gene encoding Artemis (Dclre1c/Art; Rooney et al., 2004b) were crossed with Trp53 heterozygous mice to produce doubly heterozygous 129Sv/C57BL/6 Art N/ þ Trp53 N/ þ mice. These were backcrossed to C57BL/6 Art N/N mice, and progeny were crossed to generate N/ þ cohorts were tested using a log-rank test of survival analysis in JMP6.0 (SAS Institute Inc., Cary, NC, USA).
Histology and flow cytometry
For histological analysis, tissues were fixed in Bouins fixative, paraffin embedded and sections stained with hematoxylin and eosin (H&E). Tumor tissue was processed for genomic DNA, total RNA and metaphase chromosome spreads (see below). Genomic DNA was prepared by phenol chloroform extraction and isopropanol precipitation. Tumor tissue was soaked overnight in RNALater, and stored at À201C, or further processed by Trizol extraction, according to the manufacturer's protocol for total RNA isolation.
Single cell suspensions for flow cytometry were prepared by manual disruption of isolated tissue into RPMI media þ 10% fetal calf serum. Cell suspensions were stained with either a B (IgM, B220, CD43, CD19) or T (CD3, CD4, CD8) cell diagnostic antibody cocktail. Flow cytometric analysis was performed using a Becton-Dickinson (Franklin Lakes, NJ, USA) FACSCalibur system operated with CellQuest Pro software, and analyzed using FlowJo2.0 software.
Spectral karyotyping and FISH
Metaphase chromosomes were prepared from freshly isolated lymphoma cells cultured for 3-6 h in the presence of 25 ng/ml IL-7 (R&D Systems, Minneapolis, MN, USA) and 50-100 ng/ ml colcemid (KaryoMAX, GIBCO). Metaphase chromosome preparation and SKY analysis were performed as described previously (Sharpless et al., 2001) . Fluorescence in situ hybridization was performed according to standard methods (Akeson et al., 2001 (Akeson et al., , 2006 . Slides were counterstained with DAPI and imaging was performed on a Nikon 90i upright fluorescence microscope or on an ASI cytogenetics workstation (Applied Spectral Imaging, Vista, CA, USA). The following probes were used for FISH. Chr 11: BAC1 ¼ RP23-182G20, BAC2 ¼ RP32402K16, BAC3 ¼ RP23-211J23 and BAC4 ¼ RP23-341I8; c-myc: RP23-130M17. The Igh specific BAC probe was described previously (Bassing et al., 2003) .
Array CGH Four micrograms of genomic DNA was labeled with either Cy3 or Cy5 by random octamer priming and extension, (Kerr and Churchill, 2001 ).
Quantitative PCR CancerQuantArray, a high-throughput 384-well real-time PCR platform, was utilized to measure DNA copy number changes at selected cancer-related loci (Akilesh et al., 2003; Hart et al., 2004) . Triplicate tumor DNA samples were compared with reference DNA. Cycle threshold (C t ) values were normalized using quantile normalizations, and copy number changes were estimated by ANOVA using R/ Maanova (Irizarry et al., 2003; Wu et al., 2003; Churchill, 2004) .
Trp53-specific quantitative PCR was performed using Power SYBR Green PCR Master Mix on ABI Real-Time PCR 7500 (Applied Biosystems, Foster City, CA, USA), with primers detecting a knockout allele specific sequence (NEO), a sequence shared by the wild type and null alleles (COMMON), or one of four reference sequences (Cd28, Lck, Prkcd, G22p1) (Supplementary Table 3 ; Supplementary methods).
